Crawford Investment Counsel’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$147M Sell
744,724
-24,758
-3% -$4.77M 2.51% 4
2025
Q4
$141M Sell
769,482
-13,555
-2% -$2.38M 2.36% 4
2025
Q3
$120M Buy
783,037
+13,607
+2% +$2.06M 1.99% 10
2025
Q2
$108M Sell
769,430
-14,319
-2% -$2.01M 1.88% 12
2025
Q1
$115M Sell
783,749
-23,534
-3% -$3.4M 2.04% 10
2024
Q4
$106M Buy
807,283
+39,266
+5% +$5.5M 1.9% 12
2024
Q3
$120M Sell
768,017
-4,935
-0.6% -$797K 2.04% 8
2024
Q2
$121M Sell
772,952
-5,467
-0.7% -$823K 2.3% 4
2024
Q1
$105M Buy
778,419
+23,799
+3% +$3.15M 1.96% 11
2023
Q4
$102M Sell
754,620
-7,245
-1% -$942K 2.04% 9
2023
Q3
$103M Buy
761,865
+8,571
+1% +$1.17M 2.24% 7
2023
Q2
$108M Sell
753,294
-22,364
-3% -$3.29M 2.19% 8
2023
Q1
$108M Sell
775,658
-31,929
-4% -$4.3M 2.3% 6
2022
Q4
$110M Sell
807,587
-6,662
-0.8% -$835K 2.36% 8
2022
Q3
$89.3M Sell
814,249
-8,324
-1% -$1.06M 2.11% 11
2022
Q2
$109M Sell
822,573
-48,457
-6% -$6.36M 2.4% 7
2022
Q1
$116M Sell
871,030
-22,971
-3% -$2.75M 2.24% 5
2021
Q4
$104M Buy
894,001
+2,687
+0.3% +$316K 1.98% 11
2021
Q3
$107M Buy
891,314
+1,967
+0.2% +$229K 2.19% 6
2021
Q2
$107M Sell
889,347
-56,352
-6% -$6.18M 2.15% 9
2021
Q1
$94M Buy
945,699
+39,374
+4% +$3.96M 2.12% 10
2020
Q4
$90.6M Sell
906,325
-6,260
-0.7% -$663K 2.24% 10
2020
Q3
$100M Buy
912,585
+3,370
+0.4% +$375K 2.73% 5
2020
Q2
$96.2M Sell
909,215
-44,144
-5% -$4.56M 2.76% 4
2020
Q1
$85.2M Buy
953,359
+39,248
+4% +$3.69M 2.86% 2
2019
Q4
$91.2M Buy
914,111
+108,463
+13% +$10.2M 2.36% 4
2019
Q3
$71.8M Sell
805,648
-5,603
-0.7% -$486K 1.99% 16
2019
Q2
$67M Sell
811,251
-10,727
-1% -$841K 1.89% 20
2019
Q1
$66.5M Sell
821,978
-8,000
-1% -$631K 1.98% 17
2018
Q4
$63M Sell
829,978
-41,518
-5% -$3.24M 2.14% 15
2018
Q3
$69M Buy
871,496
+8,262
+1% +$625K 2.1% 15
2018
Q2
$60.6M Buy
863,234
+55,243
+7% +$3.97M 1.93% 20
2018
Q1
$56.5M Buy
807,991
+507,060
+168% +$35.1M 1.78% 24
2017
Q4
$20.9M Buy
300,931
+5,104
+2% +$344K 0.65% 48
2017
Q3
$20M Buy
295,827
+79,398
+37% +$5.02M 0.65% 48
2017
Q2
$14.8M Sell
216,429
-60,625
-22% -$3.96M 0.51% 57
2017
Q1
$17.3M Buy
277,054
+26,572
+11% +$1.55M 0.61% 44
2016
Q4
$13.7M Buy
250,482
+15,364
+7% +$872K 0.5% 49
2016
Q3
$15.5M Buy
235,118
+42,195
+22% +$2.76M 0.57% 48
2016
Q2
$11.6M Buy
192,923
+42,085
+28% +$2.44M 0.46% 49
2016
Q1
$8.49M Buy
150,838
+145,068
+2,514% +$8.72M 0.36% 56
2015
Q4
$392K Sell
5,770
-910
-14% -$59.7K 0.02% 199
2015
Q3
$425K Buy
6,680
+435
+7% +$28.6K 0.02% 203
2015
Q2
$398K Sell
6,245
-34,210
-85% -$2.34M 0.02% 202
2015
Q1
$2.77M Buy
40,455
+625
+2% +$43.4K 0.1% 85
2014
Q4
$2.8M Sell
39,830
-2,745
-6% -$197K 0.1% 86
2014
Q3
$3.04M Buy
42,575
+18,900
+80% +$1.38M 0.11% 82
2014
Q2
$1.76M Sell
23,675
-29,190
-55% -$2.11M 0.06% 91
2014
Q1
$3.43M Sell
52,865
-119,720
-69% -$7.73M 0.12% 67
2013
Q4
$10.2M Buy
172,585
+5,390
+3% +$293K 0.38% 39
2013
Q3
$8.68M Buy
167,195
+5,670
+4% +$285K 0.34% 40
2013
Q2
$7.64M Buy
+161,525
New +$8.22M 0.32% 43

Other funds holding AZN

Crawford Investment Counsel's AZN Position: Q1 2026 in Review

Crawford Investment Counsel reduced its AstraZeneca (AZN) stake by 3.2% in Q1 2026, selling an estimated $4.77M and leaving 744,724 shares worth $147M. The position accounts for 2.51% of the portfolio, ranked #4.

Crawford Investment Counsel first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Crawford Investment Counsel held 744,724 shares of AstraZeneca worth $147M as of Q1 2026.
  • Crawford Investment Counsel sold 24,758 AstraZeneca shares in Q1 2026, an estimated $4.77M.
  • AstraZeneca made up 2.51% of Crawford Investment Counsel's portfolio in Q1 2026, its #4 holding.
  • Crawford Investment Counsel first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
  • 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Crawford Investment Counsel's 13F filing for Q1 2026, filed 15 May 2026.